Abstract

OBJECTIVE: This study was conducted this study to compare the efficacy of metformin and pioglitazone in restoring ovulation and their effect on pregnancy.

BACKGROUND: Polycystic ovarian syndrome is a prevalent complex condition that affects 5-20% of women of reproductive age. PCOS symptoms include an ovulatory cycle indicators, high serum androgen levels, hirsutism, inflammatory acne, and infertility. Clinical studies have suggested that insulin sensitizers such as metformin (dimethyl biguanide) and pioglitazone are effective in treating PCOS, which is characterized by insulin resistance.

MATERIALS AND METHODS: A Comparative analysis study was conducted using single blind randomization at Gynecology and Obstetrics wards at Civil Hospital,  LUMHS Hyderabad from September 2023 to March 2024. 110 patients were divided into two groups A and B (55 in each group). Pioglitazone was given to group A and Metformin was given to group B. The data was entered and analyzed using IBM SPSS version 26.0

RESULTS: Out of the 110 study subjects, 55 patients with PCOS received pioglitazone and 55 patient’s metformin. The mean was 32.4 ±2.56 and30.7 ±2.12 years while mean BMI was 25.4± 1.61 Kg/m² and 26.7±2.21 Kg/m² in group A and B respectively. 38 (70.37%) of the patient receiving pioglitazone reported to conceive and 16(29.63%) in metformin group. 42 (57.53%) and 31 (42.47%) confirmed ovulation While 12 (24%) and 38 (76%) reported to have pregnancy in pioglitazone group and metformin group respectively.

CONCLUSION:  Metformin and pioglitazone both help treat PCOS by decreasing hyperandrogenism, restoring ovulation, and regulating menstrual cycles. Both are interchangeably useful in the treatment of PCOS.